Last reviewed · How we verify

ketoprofen in Diractin® — Competitive Intelligence Brief

ketoprofen in Diractin® (ketoprofen in Diractin®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID. Area: Pain management, Inflammation.

phase 3 NSAID COX-1 and COX-2 Pain management, Inflammation Small molecule Live · refreshed every 30 min

Target snapshot

ketoprofen in Diractin® (ketoprofen in Diractin®) — IDEA AG. Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ketoprofen in Diractin® TARGET ketoprofen in Diractin® IDEA AG phase 3 NSAID COX-1 and COX-2
Cytotec Misoprostol Pfizer marketed NSAID combined with prostaglandin analog Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors 1988-01-01
Ibuprofen Acid Ibuprofen Acid Reckitt Benckiser Healthcare (UK) Limited marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1 and COX-2
Diclofenac 1% Diclofenac 1% Daré Bioscience, Inc. marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1 and COX-2
Ropivacaine, Ketorolac and Adrenaline Ropivacaine, Ketorolac and Adrenaline University of Aarhus marketed Local anesthetic combination with NSAID and vasopressor Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac); alpha and beta adrenergic receptors (adrenaline)
ABS ABS Teva Branded Pharmaceutical Products R&D, Inc. marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1 and COX-2
DICL-SR DICL-SR Kunming Baker Norton Pharmaceutical Sales Co., Ltd. marketed NSAID (nonsteroidal anti-inflammatory drug) COX-1 and COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID class)

  1. Antibe Therapeutics Inc. · 3 drugs in this class
  2. Iroko Pharmaceuticals, LLC · 3 drugs in this class
  3. Organon and Co · 2 drugs in this class
  4. Apsen Farmaceutica S.A. · 2 drugs in this class
  5. Amneal Pharmaceuticals, LLC · 2 drugs in this class
  6. Behar, Caren, M.D. · 2 drugs in this class
  7. IDEA AG · 2 drugs in this class
  8. Noven Pharmaceuticals, Inc. · 2 drugs in this class
  9. HALEON · 2 drugs in this class
  10. Pfizer · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ketoprofen in Diractin® — Competitive Intelligence Brief. https://druglandscape.com/ci/ketoprofen-in-diractin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: